Detalles de la búsqueda
1.
Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease.
Hepatology;
2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38768142
2.
A new imaging classification for safer radial access visceral intervention of the liver and optimal case selection: A preliminary report.
Hepatol Res;
54(5): 479-486, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38112258
3.
Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver disease.
Hepatol Res;
54(1): 54-66, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37715600
4.
Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021.
Hepatol Res;
2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38638067
5.
Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals.
Oncology;
101(2): 79-88, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36273459
6.
Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer.
Oncology;
101(11): 738-752, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37651985
7.
The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis.
Oncology;
101(2): 134-144, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36103864
8.
Impact of fibrosis on liver-related event incidence in nonalcoholic fatty liver disease: A multicenter observational study.
Hepatol Res;
53(12): 1169-1184, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37534742
9.
Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors.
Hepatol Res;
53(7): 607-617, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36891614
10.
Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage.
Oncology;
100(1): 31-38, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34788749
11.
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.
Oncology;
100(6): 320-330, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35231914
12.
Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B.
Hepatol Res;
52(2): 153-164, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34687121
13.
Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma.
Ann Surg Oncol;
28(12): 7663-7672, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33904001
14.
TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Oncology;
99(2): 114-123, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-32998139
15.
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment.
Oncology;
99(10): 611-621, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34139691
16.
Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
Oncology;
99(3): 169-176, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33207358
17.
PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD.
BMC Gastroenterol;
21(1): 434, 2021 Nov 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34798835
18.
Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study.
BMC Gastroenterol;
21(1): 189, 2021 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33892649
19.
Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Hepatol Res;
51(4): 426-435, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33270344
20.
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
Hepatol Res;
51(4): 503-508, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33462964